Glen Eagle Advisors, LLC Relmada Therapeutics, Inc. Transaction History

Glen Eagle Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Aug 13, 2024	SELL	$16.93 - $26.82 $423 - $670	-25 Closed	0 $0
Q4 2020 Aug 13, 2024	BUY	$29.88 - $39.8 $747 - $994	25 New	25 $802,000
Q4 2019 Aug 13, 2024	BUY	$10.1 - $47.18 $252 - $1,179	25 New	25 $975,000
Q3 2019 Aug 13, 2024	BUY	$6.76 - $11.6 $0 - $0	0 New	0 $0

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.3M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Glen Eagle Advisors, LLC with notifications on news.